Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Curr Opin Hematol. 2018 Jul;25(4):245-252. doi: 10.1097/MOH.0000000000000429.
Allogeneic hematopoietic cell transplantation (HCT) is a life-saving therapy for hematological and nonhematological diseases. Cord blood is a source of transplantable hematopoietic stem cells (HSCs), but limited numbers of HSCs in single cord blood units, which may cause delayed neutrophil, platelet, and immune cell reconstitution, is a major problem for efficient transplantation. Ex-vivo expansion and enhanced homing of cord blood HSC may overcome this disadvantage and improve its long-term engraftment. Here, we discuss the role of nuclear hormone receptors signaling in human cord blood HSC engraftment.
Antagonizing retinoid acid receptor (RAR) signaling promotes human HSC expansion and increases myeloid cell production. Cord blood CD34 cells expanded by SR1 promotes efficient myeloid recovery after transplantation compared with control groups, and leads to successful engraftment. Short-term treatment of glucocorticoids enhances homing and long-term engraftment of human HSCs and HPCs in NSG mice. Peroxisome proliferator-activated receptor-γ (PPARγ) antagonism expands human HSCs and HPCs by preventing differentiation and enhancing glucose metabolism. These findings demonstrate that nuclear hormone receptor signaling components might be promising targets for improving human cord blood HCT.
Better understanding of molecular mechanisms underlying human HSC expansion and homing mediated by nuclear hormone receptor signaling pathways will facilitate enhanced HCT efficacy.
异基因造血细胞移植(HCT)是治疗血液系统和非血液系统疾病的救命疗法。脐带血是移植造血干细胞(HSCs)的来源,但单个脐带血单位中 HSCs 的数量有限,这可能导致中性粒细胞、血小板和免疫细胞重建延迟,是高效移植的主要问题。体外扩增和增强脐带血 HSC 的归巢可能克服这一劣势,改善其长期植入。在这里,我们讨论了核激素受体信号在人脐带血 HSC 植入中的作用。
拮抗视黄酸受体(RAR)信号可促进人 HSC 扩增并增加髓系细胞的产生。与对照组相比,SR1 扩增的脐带血 CD34 细胞可促进移植后髓系细胞的有效恢复,并导致成功植入。短期糖皮质激素治疗可增强人 HSCs 和 HPCs 在 NSG 小鼠中的归巢和长期植入。过氧化物酶体增殖物激活受体-γ(PPARγ)拮抗剂通过防止分化和增强葡萄糖代谢来扩增人 HSCs 和 HPCs。这些发现表明,核激素受体信号通路的分子机制可能是改善人脐带血 HCT 的有前途的靶点。
更好地了解核激素受体信号通路介导的人 HSC 扩增和归巢的分子机制将有助于增强 HCT 疗效。